Vol. 14 No. 2 (2021): A Year after the Pandemic

COVID-19 Summary Guidelines

Samuel Moses
Wales Health Board
Nidhika Berry
Wales Health Board
Professor Atul Kalhan
Wales Health Board
Sonia Sathe
Wales Health Board
Latha Srinivasan
Wales Health Board
Viju Varadarajan
Wales Health Board
Hasmukh Shah
Wales Health Board
Prof. Keshav Singhal MBE FLSW
University of Swansea, Wales, UK

Published 2021-06-01


  • COVID-19,
  • Guidelines,
  • Sars-CoV-2

How to Cite

Moses, S., Berry, N., Kalhan, A., Sathe, S., Srinivasan, L., Varadarajan, V., Shah, H., & Singhal, K. (2021). COVID-19 Summary Guidelines. Sushruta Journal of Health Policy & Opinion, 14(2), 1–5. https://doi.org/10.38192/14.2.4


Low and Medium Income Countries- May 2021

We note with concern, potential misinformation regarding treatment options is recommended to patients in India. We suggest the following evidence-based practice for the management of SARS CoV2 infection.


  1. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021;384:693–704. doi:10.1056/NEJMoa2021436
  2. The Writing Committee for the REMAP-CAP Investigators, Angus DC, Derde L, et al. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020;324:1317. doi:10.1001/jama.2020.17022
  3. Corticosteroids for COVID-19. REMAP-CAP Trial. https://www.remapcap.org/covid19publications/corticosteroid-for-covid-19 (accessed 1 Jun 2021).
  4. Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Critical Care Medicine 2020;48:e440–69. doi:10.1097/CCM.0000000000004363
  5. prone_position_in_adult_critical_care_2019.pdf. https://www.ficm.ac.uk/sites/default/files/prone_position_in_adult_critical_care_2019.pdf (accessed 1 Jun 2021).
  6. Bamford P, Bentley A, Dean J, et al. ICS Guidance for Prone Positioning of the Conscious COVID Patient 2020. ;:6.
  7. INSPIRATION Investigators, Mazloomzadeh S, Khaleghparast S, et al. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial. JAMA 2021;325:1620. doi:10.1001/jama.2021.4152
  8. CAS-ViewAlert. https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103129 (accessed 1 Jun 2021).
  9. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) | The BMJ. https://www.bmj.com/content/371/bmj.m3939 (accessed 1 Jun 2021).
  10. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial | medRxiv. https://www.medrxiv.org/content/10.1101/2021.03.09.21252736v1 (accessed 1 Jun 2021).
  11. Convalescent Plasma for COVID-19. REMAP-CAP Trial. https://www.remapcap.org/covid19publications/convalescent-plasma-for-covid-19 (accessed 1 Jun 2021).
  12. Convalescent plasma is ineffective for covid-19 | The BMJ. https://www.bmj.com/content/371/bmj.m4072 (accessed 1 Jun 2021).
  13. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 | NEJM. https://www.nejm.org/doi/10.1056/NEJMoa2022926 (accessed 1 Jun 2021).
  14. azithromycin-recovery-statement-141220_final.pdf. https://www.recoverytrial.net/files/azithromycin-recovery-statement-141220_final.pdf (accessed 1 Jun 2021).
  15. Gautret P, Lagier J-C, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020;:105949. doi:10.1016/j.ijantimicag.2020.105949
  16. Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med Published Online First: 18 March 2020. doi:10.1056/NEJMoa2001282
  17. Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial - The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32013-4/fulltext (accessed 1 Jun 2021).
  18. REMAP-CAP Investigators, Gordon AC, Mouncey PR, et al. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med 2021;384:1491–502. doi:10.1056/NEJMoa2100433
  19. Group RC, Horby PW, Pessoa-Amorim G, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv 2021;:2021.02.11.21249258. doi:10.1101/2021.02.11.21249258
  20. Della-Torre E, Campochiaro C, Cavalli G, et al. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis 2020;79:1277–85. doi:10.1136/annrheumdis-2020-218122
  21. PINHO AC. EMA advises against use of ivermectin for the prevention or treatment COVID-19 outside randomised clinical trials. European Medicines Agency. 2021.https://www.ema.europa.eu/en/news/ema-advises-against-use-ivermectin-prevention-treatment-covid-19-outside-randomised-clinical-trials (accessed 1 Jun 2021).
  22. WHO advises that ivermectin only be used to treat COVID-19 within clinical trials. https://www.who.int/news-room/feature-stories/detail/who-advises-that-ivermectin-only-be-used-to-treat-covid-19-within-clinical-trials (accessed 1 Jun 2021).
  23. Chakravorty S. Vaccines against SARS-Cov-2: An Unprecedented Scientific Triumph and a Source of Hope in the Pandemic. phy 2021;6:1–3. doi:10.38192/
  24. The effects of virus variants on COVID-19 vaccines. https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines (accessed 1 May 2021).